Hydrodynamic delivery of human IL-15 cDNA increases murine natural killer cell recovery after syngeneic bone marrow transplantation

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 12, 2011, Pages 1754-1764

  Barao, Isabel ^a   Alvarez, Maite ^b   Redelman, Doug ^c   Weiss, Jonathan M ^d   Ortaldo, John R ^d   Wiltrout, Robert H ^d   Murphy, William J ^b  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NEVADA   (United States)

^d SAIC FREDERICK INC   (United States)

Author keywords

Bone marrow transplantation; Gene therapy; IL 15; NK reconstitution

Indexed keywords

COMPLEMENTARY DNA; INTERLEUKIN 15;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER RELAPSE; CELL FUNCTION; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOLYSIS; DRUG CYTOTOXICITY; FEMALE; GENE TRANSFER; HYDRODYNAMICS BASED TRANSFECTION; IMMUNE DEFICIENCY; IN VITRO STUDY; INFECTION RESISTANCE; INFECTION SENSITIVITY; KIDNEY CARCINOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; OPPORTUNISTIC INFECTION; PHENOTYPE; PLASMID; QUANTITATIVE ANALYSIS; RECIPIENT; STEM CELL;

ANIMALS; BONE MARROW TRANSPLANTATION; CARCINOMA, RENAL CELL; DISEASE MODELS, ANIMAL; DNA, COMPLEMENTARY; FEMALE; GENE THERAPY; HUMANS; INTERLEUKIN-15; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL;

EID: 81255160752     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.08.023     Document Type: Article

References (38)

1. Marks D.I., Cullis J.O., Ward K.N., et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years. Ann Intern Med 1993, 119:207-214.
2. Speiser D.E., Tiercy J.M., Rufer N., et al. High resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation. Blood 1996, 87:4455-4462.
3. Davies S.M., Shu X.O., Blazar B.R., et al. Unrelated donor bone marrow transplantation: influence of HLA A and B incompatibility on outcome. Blood 1995, 86:1636-1642.
4. Alpdogan O., Schmaltz C., Muriglan S.J., et al. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease. Blood 2001, 98:2256-2265.
5. Rosenberg S.A. Progress in the development of immunotherapy for the treatment of patients with cancer. J Intern Med 2001, 250:462-475.
6. Miller J.S. Biology of natural killer cells in cancer and infection. Cancer Invest 2002, 20:405-419.
7. Storek J., Geddes M., Khan F., et al. Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Semin Immunopathol 2008, 30:425-437.
8. Barao I., Murphy W.J. The immunobiology of natural killer cells and bone marrow allograft rejection. Biol Blood Marrow Transplant 2003, 9:727-741.
9. Suda T., Liu D. Hydrodynamic gene delivery: its principles and applications. Mol Ther 2007, 15:2063-2069.
10. Ortaldo J.R., Winkler-Pickett R.T., Bere E.W., Watanabe M., Murphy W.J., Wiltrout R.H. In vivo hydrodynamic delivery of cDNA encoding IL-2: rapid, sustained redistribution, activation of mouse NK cells, and therapeutic potential in the absence of NKT cells. J Immunol 2005, 175:693-699.
11. Ma A., Koka R., Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol 2006, 24:657-679.
12. Carson W.E., Fehniger T.A., Haldar S., et al. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest 1997, 99:937-943.
13. Cooper M.A., Fehniger T.A., Turner S.C., et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001, 97:3146-3151.
14. Barao I., Hanash A.M., Hallett W., et al. Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells. Proc Natl Acad Sci USA 2006, 103:5460-5465.
15. Barao I., Alvarez M., Ames E., et al. Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independently of MHC. Blood 2011, 117:7032-7041.
16. Kennedy M.K., Glaccum M., Brown S.N., et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000, 191:771-780.
17. Cooper M.A., Bush J.E., Fehniger T.A., et al. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 2002, 100:3633-3638.
18. Castillo E.F., Stonier S.W., Frasca L., Schluns K.S. Dendritic cells support the in vivo development and maintenance of NK cells via IL-15 trans-presentation. J Immunol 2009, 183:4948-4956.
19. McCullar V., Oostendorp R., Panoskaltsis-Mortari A., et al. Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56-negative natural killer cell precursors in the absence of interleukin-15. Exp Hematol 2008, 36:598-608.
20. Peschon J.J., Morrissey P.J., Grabstein K.H., et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med 1994, 180:1955-1960.
21. Satoh-Takayama N., Lesjean-Pottier S., Vieira P., et al. IL-7 and IL-15 independently program the differentiation of intestinal CD3-NKp46+ cell subsets from Id2-dependent precursors. J Exp Med 2010, 207:273-280.
22. Orr M.T., Murphy W.J., Lanier L.L. "Unlicensed" natural killer cells dominate the response to cytomegalovirus infection. Nat Immunol 2010, 11:321-327.
23. Miller J.S., McCullar V. Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2. Blood 2001, 98:705-713.
24. Elpek K.G., Rubinstein M.P., Bellemare-Pelletier A., Goldrath A.W., Turley S.J. Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Ralpha complexes. Proc Natl Acad Sci USA 2010, 107:21647-21652.
25. Alpdogan O., Eng J.M., Muriglan S.J., et al. Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood 2005, 105:865-873.
26. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105:3051-3057.
27. Pillet A.H., Bugault F., Theze J., Chakrabarti L.A., Rose T. A programmed switch from IL-15- to IL-2-dependent activation in human NK cells. J Immunol 2009, 182:6267-6277.
28. Giron-Michel J., Giuliani M., Fogli M., et al. Membrane-bound and soluble IL-15/IL-15Ralpha complexes display differential signaling and functions on human hematopoietic progenitors. Blood 2005, 106:2302-2310.
29. Huntington N.D., Legrand N., Alves N.L., et al. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med 2009, 206:25-34.
30. Phan G.Q., Attia P., Steinberg S.M., White D.E., Rosenberg S.A. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001, 19:3477-3482.
31. Overwijk W.W., Schluns K.S. Functions of gammaC cytokines in immune homeostasis: current and potential clinical applications. Clin Immunol 2009, 132:153-165.
32. Rosenstein M., Ettinghausen S.E., Rosenberg S.A. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 1986, 137:1735-1742.
33. Katsanis E., Xu Z., Panoskaltsis-Mortari A., Weisdorf D.J., Widmer M.B., Blazar B.R. IL-15 administration following syngeneic bone marrow transplantation prolongs survival of lymphoma bearing mice. Transplantation 1996, 62:872-875.
34. Thiant S., Labalette M., Trauet J., et al. Plasma levels of IL-7 and IL-15 after reduced intensity conditioned allo-SCT and relationship to acute GVHD. Bone Marrow Transplant 2010.
35. Roychowdhury S., Blaser B.W., Freud A.G., et al. IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease. Blood 2005, 106:2433-2435.
36. Blaser B.W., Roychowdhury S., Kim D.J., et al. Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease. Blood 2005, 105:894-901.
37. Blaser B.W., Schwind N.R., Karol S., et al. Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity. Blood 2006, 108:2463-2469.
38. Chen G., Wu D., Wang Y., et al. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation. Eur J Haematol 2008, 81:226-235.